Inhibikase Therapeutics Inc. (IKT) saw an uptrend of 6.67% in the recent trading with $2.40 being its most recent. The current price level -79.66% lower than the highest price of $11.80 marked by the stock while trading over the past 52-weeks, whereas it is 9.09% higher than the lowest price of $2.20 the company dropped to over past 52-weeks. The latest news story on IKT appeared in PR Newswire under the title “Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock” on Jun-18-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -22.08% below one month high and is +9.09% above of the lowest during that time. Looking into the simple moving average, Inhibikase Therapeutics Inc. (IKT)’s stock stands at a SMA-50 of $4.00 while that of 5-day is reading $2.41.
Inhibikase Therapeutics Inc. Earnings – What Happened With IKT
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $1.41 billion.
IKT – Inhibikase Therapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 10.05 million. IKT does have institutional investors; and they hold 12.50% of the stock.
Inhibikase Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 43,707 shares. On the other hand, IKT declared 16,918 shares have been sold in 1 insider transactions over the past three months.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Inhibikase Therapeutics Inc. was 3.13 while posting a debt to equity ratio of 0.15. The count was 2.83 for long-term debt to equity ratio.
Inhibikase Therapeutics Inc.’s return on equity, or ROE, is -251.10%, compared to the industry average of -38.26% for Healthcare – Biotechnology. Although this indicates that IKT fails to use its equity well, the metric will vary significantly depending on the industry.